European DES Market Gains New Offerings From Boston Scientific, Abbott
This article was originally published in The Gray Sheet
Executive Summary
Competition is heating up in the European drug-eluting stent space, as Boston Scientific launches its third-generation Promus Element stent and Abbott offers expanded indications for Xience V and Xience Prime for diabetes patients